Novartis AG

NVSNYSE • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
156.08 USD
↘ 0.78 (0.50%)AT CLOSE (03:59 PM EDT)
156.39
↗ 0.31 (0.20%)
POST MARKET (AS OF 05:05 PM EDT)
Post Market
AS OF 05:05 PM EDT
156.39
↗ 0.31 (0.20%)
🟢Market: OPEN

NVS is currently priced at $156.39. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score and a bearish Death Cross on the long-term moving averages. On the valuation front, NVS trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Oct 28, 2026.

Open?$154.86
High?$157.41
Low?$154.11
Prev. Close?$156.86
Volume?1.9M
Avg. Volume?2.0M
VWAP?$156.26
Rel. Volume?0.98x
Bid / Ask
Bid?$155.00 × 200
Ask?$157.00 × 100
Spread?$2.00
Midpoint?$156.00
Valuation & Ratios
Market Cap?296.2B
Shares Out?2.0B
P/E Ratio?43.84
P/B Ratio?4.09
EPS?$3.58
Dividend?2.19%
Ex-Dividend?N/A
News
Profile
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
75.3K
Market Cap
296.2B
Industry
N/A
Website
www.novartis.com
Listed
1996-11-07
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
99
Momentum?
35
Short Sent.?
60
Piotroski F-Score?3/9Weak
Altman Z-Score?5.53Safe
Confidence?60%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short Interest?5.6M
Days to Cover?3.2
Avg Daily Volume1.7M
Settlement Date2026-10-15
Financial Health
Current Ratio?0.90Weak
Quick Ratio?0.65Weak
Cash Ratio?0.22Low
Debt/Equity?0.22Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
Peers
100
S&P
16
43.8PRICEY▾
P/B?
Peers
100
S&P
44
4.09FAIR▾
P/S?
Peers
100
S&P
22
5.95FAIR▾
P/FCF?
Peers
100
S&P
28
30.6FAIR▾
EV/EBITDA?
Peers
100
S&P
17
24.3HIGH▾
EV/Sales?
Peers
100
S&P
27
6.16HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
31
9.3%FAIR▾
ROA?
Peers
50
S&P
46
5.1%FAIR▾
Cash Flow & Enterprise
FCF?$9.7B
Enterprise Value?$306.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist